Could a weekly pill replace daily HIV meds? new trial investigates
NCT ID NCT06891066
Summary
This study is testing if a new combination of two drugs (islatravir and ulonivirine), taken just once a week, can keep HIV under control as effectively as a standard daily pill regimen. It will involve about 150 adults whose HIV is already well-managed on daily medication. The main goal is to see if the weekly treatment is safe and prevents the virus from rebounding over 24 weeks.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) INFECTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Central Texas Clinical Research ( Site 4100)
Austin, Texas, 78705, United States
-
Chatham County Health Department - Chatham CARE Center ( Site 4116)
Savannah, Georgia, 31401, United States
-
Clinical Research Puerto Rico ( Site 4300)
San Juan, 00909, Puerto Rico
-
DCOL Center for Clinical Research ( Site 4112)
Longview, Texas, 75605, United States
-
Georgetown University Medical Center ( Site 4106)
Washington D.C., District of Columbia, 20007, United States
-
HOPE Clinical Research ( Site 4303)
San Juan, 00909, Puerto Rico
-
Hôpitaux Universitaires de Genève (HUG)-Infectious Disease Department ( Site 4404)
Geneva, Canton of Geneva, 1205, Switzerland
-
Inselspital Bern-Inselspital Infektiologie ( Site 4403)
Bern, Canton of Bern, 3010, Switzerland
-
KC CARE Health Center ( Site 4101)
Kansas City, Missouri, 64111, United States
-
Mills Clinical Research ( Site 4109)
West Hollywood, California, 90046, United States
-
Momentum Clinical Research - Darlinghurst ( Site 4260)
Darlinghurst, New South Wales, 2010, Australia
-
Momentum Clinical Research Fortitude Valley ( Site 4261)
Fortitude Valley, Queensland, 4006, Australia
-
Orlando Immunology Center ( Site 4103)
Orlando, Florida, 32803, United States
-
Ospedale Regionale di Lugano, Sede Civico-Servizio Malattie Infettive ( Site 4405)
Lugano, Canton Ticino, 6900, Switzerland
-
Ponce Medical School Foundation Inc./CAIMED Center ( Site 4301)
Ponce, 00716, Puerto Rico
-
Prahran Market Clinic ( Site 4262)
Prahran, Victoria, 3181, Australia
-
Prism Health North Texas, Oak Cliff Health Center ( Site 4114)
Dallas, Texas, 75208, United States
-
Regional Center for Infectious Diseases ( Site 4115)
Greensboro, North Carolina, 27401, United States
-
St. Vincent's Hospital ( Site 4263)
Darlinghurst, New South Wales, 2010, Australia
-
The Alfred Hospital ( Site 4264)
Melbourne, Victoria, 3004, Australia
-
Triple O Research Institute ( Site 4111)
West Palm Beach, Florida, 33407, United States
-
University Hospital Basel-Infectiology ( Site 4402)
Basel, Canton of Basel-City, 4031, Switzerland
-
Zuckerberg San Francisco General Hospital and Trauma Center ( Site 4107)
San Francisco, California, 94110, United States
Conditions
Explore the condition pages connected to this study.